Core One Labs (COOL.C) announced they have acquired all outstanding share capital of Bluejay Mental Health, a specialty medical clinic with an integrated telehealth platform. Bluejay’s integrated telehealth platform…
COOL.C
Core One Labs (COOL.C) has announced they are collaborating with Ketamine Infusions Centers of Texas (KICT) to explore the development of a program for N-dimethyltryptamine (DMT) assisted psychotherapy to…
Core One Labs’ (COOL.C) wholly-owned subsidiary Vocan Biotechnologies has entered into a term sheet with Vocan Brazil Biotechnologies (Vocan Brazil) for the licensing of its proprietary technology, biosynthesized psilocybin….
Core One Labs (COOL.C) reported today that they’re ready to start biosynthetic production trials with psilocybin, according to a press release. The company’s Victoria-based subsidiary, Vocan Biotechnologies, finished developing…
Core One Labs (COOL.C) signed a letter of intent today with Ketamine Infusion Centers of Texas (KICT) today to determine if the company would be an adequate fit for…
Core One Labs (COOL.C) subsidiary Vocan Biotechnologies finished putting together the required equipment to start artificially producing psilocybin today, according to a press release. Acquired in December, Vocan has…
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and…
“This transaction will significantly enhance Core One Labs’ ability to innovate our psychedelic drug development program,” stated Joel Shacker, CEO of Core Labs….
In my experience with the North American public markets, few companies and executive teams got more lucky with their shareholder base than Lifestyle Delivery Systems. Their initial pitch was…